<DOC>
	<DOCNO>NCT01936363</DOCNO>
	<brief_summary>This double blind , randomize , placebo-controlled , 2-arm , Phase 2 trial investigate efficacy safety combination therapy pimasertib plus SAR245409 pimasertib placebo administer per day compare pimasertib administer twice per day plus SAR245409 placebo administer per day subject previously treat unresectable low-grade serous ovarian peritoneal carcinoma serous borderline ovarian peritoneal tumor .</brief_summary>
	<brief_title>Trial Pimasertib With SAR245409 Placebo Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>The female subject diagnosis one following : ) lowgrade serous ovarian peritoneal carcinoma , grade 1 serous ovarian peritoneal carcinoma welldifferentiated serous ovarian peritoneal carcinoma b ) serous borderline ovarian peritoneal tumor , ovarian peritoneal tumor lowmalignant potential , ovarian peritoneal atypical proliferative serous tumor recurs low grade serous carcinoma invasive peritoneal implant . The subject least one prior line systemic therapy tumor , amenable potentially curative surgical resection . The subject measurable disease Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 . The subject least 18 year old . The subject read understood write informed consent form ( ICF ) willing able give inform consent , fully understand requirement trial willing comply trial visit assessment , include completion patientreported measure . Consent must give trial related activity . Women childbearing potential must negative serum pregnancy test screen visit . Women childbearing potential must willing avoid pregnancy use adequate method contraception 2 week prior screen , least 3 month last dose trial medication . Other protocol define inclusion criterion may apply . The subject previously treat PI3K inhibitor take treatment due treatment related AEs . The subject previously treat Mitogenactivated protein/extracellular signalregulated kinase ( MEK ) inhibitor . Any anticancer therapy treatment incorporate chemotherapy , immunotherapy , hormonal therapy , biologic therapy within 28 day start trial treatment within 5 time half life treatment , whichever short . Treatment nitrosoureas mitomycin C exception treatment interval least 6 week require The subject recover toxicity due prior therapy Baseline level National Cancer Institute Common Terminology Criteria Adverse Events Version 4.0 ( NCI CTCAE v4.0 ) Grade 1 less ( except alopecia ) . Residual chemotherapyinduced neuropathy grade less equal ( &lt; = ) 2 permit . The subject poor organ marrow function define protocol . The subject creatine phosphokinase ( CPK ) elevation NCI CTCAE grade great equal ( &gt; = ) 2 , and/or previous history myositis rhabdomyolysis . The subject difficulty swallowing , malabsorption chronic gastrointestinal disease condition may hamper compliance and/or absorption trial drug . Subjects require total parenteral nutrition exclude . The subject history delay healing/open wound diabetic ulcer . The subject history congestive heart failure , unstable angina , myocardial infarction , cardiac conduction abnormality include Fridericia correct QT interval ( QTcF ) prolongation &gt; 480 millisecond ( m ) pacemaker , clinically relevant impair cardiovascular function ( New York Heart Association ( NYHA ) class III/IV ) stroke within 3 month prior enrollment . The subject history retinal degenerative disease ( hereditary retinal degeneration agerelated macular degeneration ) , uveitis retinal vein occlusion ( RVO ) , relevant abnormality identify screen opthalmologic examination , may increase risk serous retinal detachment ( SRD ) RVO . The subject history uncontrolled intercurrent illness include limited active infection , hypertension , uncontrolled diabetes ( e.g . glycosylated hemoglobin &gt; = 8 percent [ % ] ) would limit compliance treatment requirement . Any previous malignancy treat curative intent subject disease free less 5 year prior randomization , exception Carcinoma‐in‐situ cervix , Squamous carcinoma skin , Basal cell carcinoma skin . Other protocol define exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Pimasertib</keyword>
	<keyword>Placebo</keyword>
	<keyword>SAR245409</keyword>
</DOC>